TAS2R38 Taster Variants-Linked MGAM Expression in Alzheimer’s Disease: A Novel Target for Precision Drug Repurposing
Preprint
Abstract
Objective TAS2R38 is a taste receptor implicated in innate immunity. Identifying its genetic connection with Alzheimer’s disease (AD) could aid in developing new drugs or repurposing existing ones for treatment. Methods We examined the relationship between TAS2R38 taster variants and AD risk using linear mixed-effects models, utilizing data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (n = 2,342). We investigated molecular mechanisms of the association by identifying expression quantitative trait loci (eQTLs) using RNA-seq data from postmortem tissues from the Religious Orders Study/Memory and Aging Project (ROSMAP) (n = 947). We evaluated whether FDA-approved drugs targeting the identified gene could reduce dementia risk using 1:1 propensity score-matched groups in the National Alzheimer’s Coordinating Center (NACC) study, comparing cognitive performance between drug-taking and non-taking patients with linear mixed-effects models (n = 76). Results TAS2R38 supertasters were linked to reduced AD risk with advancing age in various AD biomarkers (P < 0.001). eQTL analysis connected the nontaster allele to increased expression of the gene MGAM in AD-affected brain regions (P < 0.001). Elevated MGAM expression was also associated with more severe Tau burdens (P < 0.05). A significant group difference was observed in clinical dementia rating (CDR) progression (P < 0.001) in various domains for individuals taking MGAM-inhibiting diabetes drugs (Acarbose and Miglitol) compared to the non-taking group. Interpretation The genetic association between TAS2R38 and AD biomarkers implicates MGAM as a novel drug target with existing FDA-approved inhibitors. This supports the potential of TAS2R38 haplotypes in guiding precision drug repurposing strategies for AD, warranting clinical trials.Keywords
This publication has 59 references indexed in Scilit:
- Alzheimer's Disease Sequencing Project release 4 whole genome sequencing datasetAlzheimer's & Dementia, 2025
- Voglibose Attenuates Amyloid Beta–Induced Memory Deficits in a Rodent Model: A Potential Alzheimer’s Therapy via Wnt Signaling ModulationMolecular Neurobiology, 2025
- Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategiesSignal Transduction and Targeted Therapy, 2024
- ADSP Phenotype Harmonization ConsortiumAlzheimer's & Dementia, 2023
- TAS2R38 bitter taste receptor and attainment of exceptional longevityScientific Reports, 2019
- Metascape provides a biologist-oriented resource for the analysis of systems-level datasetsNature Communications, 2019
- Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processingNature Genetics, 2019
- Human whole genome genotype and transcriptome data for Alzheimer’s and other neurodegenerative diseasesScientific Data, 2016
- The Genotype-Tissue Expression (GTEx) projectNature Genetics, 2013
- Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s DiseaseNeurobiology of Aging, 1997